NCE-1 Intelligence & Market Opportunity

Krazati

Adagrasib

Anticancer

Oral Tablet

Approval Date

12-Dec-22

NCE-1 Date

12-Dec-26

NCE Date

12-Dec-27

Commercial snapshot

Market performance & projections

Revenue ($M)

205

CAGR (%)

0.2752

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

267

2027

353

2028

446

2029

542

2030

644

2031

734

2032

819

Molecule profile

Details & specifications

Molecule

Adagrasib

Innovator

MIRATI THERAPEUTICS, INC

Dosage Form

Oral Tablet

Strength

200 mg

Therapeutic Category

Anticancer

Usage

To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.